|
|
|
| Establishment of Porcine (Sus scrofa) ETS1 Knockout Model Using CRISPR/Cas9 Gene Editing System |
| LI Shuai-Peng1,2, ZHANG Yan-Yan2,3, ZOU Guo-Wei2, RAN Lin2,3, LIN Jiang-Wei2,*, ZHANG Rui-Xian1,* |
1 The Affiliated Hospital of Kunming University of Science and Technology/The First People's Hospital of Yunnan Province, Kunming 650032, China;
2 Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650032, China;
3 College of Animal Science and Technology, Yangzhou University, Yangzhou 225009, China |
|
|
|
|
Abstract E-twenty-six proto-oncogene 1 (ETS1) gene plays an important role in autoimmune diseases (such as systemic lupus erythematosus, rheumatoid arthritis, etc.), and its deletion leads to abnormal differentiation of immune cells. The ETS1 gene has been extensively studied in the immune systems of mice (Mus musculus)and humans (Homo sapiens), but it has not been fully studied in large model animals like pigs (Sus scrofa). To investigate the role of the ETS1 gene in large model animals, this study constructed cloned pigs with an ETS1 gene knockout using gene editing technology. Firstly, the homology of the ETS1 gene in humans and pigs was analyzed through bioinformatics. Then, an ETS1 knockout cell line was constructed using CRISPR/Cas9 technology. The knockout cell line was subsequently used as the donor cell for constructing a lupus-like pig model with an ETS1 gene defect via somatic cell nuclear transfer technology. The results showed that the ETS1 amino acid sequence in pigs had high homology with humans. Fourteen monoclonal cell lines with gene deletions were obtained, including 7 with monoallelic deletions and 7 with biallelic deletions. One ETS1 monoallelic deletion pig and three wild-type pigs were successfully cloned using somatic cell nuclear transfer. This model provides a pivotal tool for elucidating the function of the ETS1 gene in the immune systems of large-animal models such as pigs, and lays the groundwork for developing large-animal models of autoimmune diseases.
|
|
Received: 24 February 2025
|
|
|
|
Corresponding Authors:
*zhangrx2005@163.com; jwlin730@hotmail.com
|
|
|
|
[1] Clements J L, John S A, Garrett-Sinha L A.2006. Impaired generation of CD8+ thymocytes in Ets-1-deficient mice[J]. Journal of Immunology, 177: 905-912.
[2] Dawson H D, Loveland J E, Pascal G, et al.2013. Structural and functional annotation of the porcine immunome[J]. BMC Genomics, 14: 332.
[3] Dittmer J.2003. The biology of the ETS1 proto-oncogene[J]. Molecular Cancer, 2: 29.
[4] Garrett-Sinha L A2023. An update on the roles of transcription factor ETS1 in autoimmune diseases[J]. WIREs Mechanisms of Disease, 15: e1627.
[5] Gupta D, Bhattacharjee O, Mandal D, et al.2019. CRISPR-Cas9 system: A new-fangled dawn in gene editing[J]. Life Sciences, 232: 116636.
[6] Islam M A, Khandker S S, Kotyla P J, et al.2020. Immunomodulatory effects of diet and nutrients in systemic lupus erythematosus (SLE): A systematic review[J]. Frontiers in Immunology, 11: 1477.
[7] Katikaneni D, Morel L, Scindia Y.2024. Animal models of lupus nephritis: The past, present and a future outlook[J]. Autoimmunity, 57: 2319203.
[8] Kawasaki A, Yamashita K, Hirano F, et al.2018. Association of ETS1 polymorphism with granulomatosis with polyangiitis and proteinase 3-anti-neutrophil cytoplasmic antibody positive vasculitis in a Japanese population[J]. Journal of Human Genetics, 63: 55-62.
[9] Kim C J, Lee C G, Jung J Y, et al.2018. The transcription factor ETS1 suppresses T follicular helper type 2 cell differentiation to halt the onset of systemic lupus erythematosus[J]. Immunity, 49: 1034-1048.e1038.
[10] Kiriakidou M, Ching C L.2020. Systemic lupus erythematosus[J]. Annals of Internal Medicine, 172: Itc81-itc96.
[11] Li Y, Sun L D, Lu W S, et al.2010. Expression analysis of ETS1 gene in peripheral blood mononuclear cells with systemic lupus erythematosus by real-time reverse transcription PCR[J]. Chinese Medical Journal, 123: 2287-2288.
[12] Lill C M, Luessi F, Alcina A, et al.2015. Genome-wide significant association with seven novel multiple sclerosis risk loci[J]. Journal of Medical Genetics, 52: 848-855.
[13] Luo W, Mayeux J, Gutierrez T, et al.2014. A balance between B cell receptor and inhibitory receptor signaling controls plasma cell differentiation by maintaining optimal ETS1 levels[J]. Journal of Immunology, 193: 909-920.
[14] Moisan J, Grenningloh R, Bettelli E, et al.2007. Ets-1 is a negative regulator of Th17 differentiation[J]. Journal of Experimental Medicine, 204: 2825-2835.
[15] Mouly E, Chemin K, Nguyen H V, et al.2010. The Ets-1 transcription factor controls the development and function of natural regulatory T cells[J]. Journal of Experimental Medicine, 207: 2113-2125.
[16] Nguyen H V, Mouly E, Chemin K, et al.2012. The Ets-1 transcription factor is required for Stat1-mediated T-bet expression and IgG2a class switching in mouse B cells[J]. Blood, 119: 4174-4181.
[17] Shan S, Dang J, Li J, et al.2014. ETS1 variants confer susceptibility to ankylosing spondylitis in Han Chinese[J]. Arthritis Research & Therapy, 16: R87.
[18] Sunshine A, Goich D, Stith A, et al.2019. ETS1 controls the development of B cell autoimmune responses in a cell-intrinsic manner[J]. Immunohorizons, 3: 331-340.
[19] Tsoi L C, Spain S L, Knight J, et al.2012. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity[J]. Nature Genetics, 44: 1341-1348.
[20] Wang D, John S A, Clements J L, et al.2005. Ets-1 deficiency leads to altered B cell differentiation, hyperresponsiveness to TLR9 and autoimmune disease[J]. International Immunology, 17: 1179-1191.
[21] Wei L, Zhou Q, Hou S, et al.2014. MicroRNA-146a and Ets-1 gene polymorphisms are associated with pediatric uveitis[J]. PLOS ONE, 9: e91199.
[22] Wen Z, Xu L, Chen X, et al.2013. Autoantibody induction by DNA-containing immune complexes requires HMGB1 with the TLR2/microRNA-155 pathway[J]. Journal of Immunology, 190: 5411-5422.
[23] Yang W, Shen N, Ye D Q, et al.2010. Genome-wide association study in Asian populations identifies variants in ETS1 and WDFY4 associated with systemic lupus erythematosus[J]. PLOS Genetics, 6: e1000841.
[24] Yu H, Nagafuchi Y, Fujio K.2021. Clinical and immunological biomarkers for systemic lupus erythematosus[J]. Biomolecules, 11(7): 928. |
|
|
|
